BioSpace News Archive

Policy

Amgen Fails to Secure FDA Adcomm Support for Full Lumakras Approval

Data from a confirmatory study could not be reliably interpreted, according to the Oncologic Drugs Advisory Committee, which voted against Amgen’s request for full approval of its G12C KRAS inhibitor.

October 6, 2023
·
2 min read
·
Tristan Manalac
Employer Resources

Webinar: Building a Culture of Inclusion

How can life science workplaces improve not only diversity but create enduring inclusivity that not only empowers employees but fosters a culture of success and mutual trust?

October 6, 2023
·
5 min read
·
Chantal Dresner
Deals

Sanofi Mulls Mirati Buy as KRAS Battle Heats Up: Bloomberg

Following a Phase III failure and the departure of its CEO, Mirati Therapeutics is rumored to be engaged in acquisition discussions with French pharma giant Sanofi, according to Bloomberg.

October 6, 2023
·
2 min read
·
Tristan Manalac
Policy

Amgen Completes $27.8B Horizon Acquisition Following FTC Challenge

After finally getting the green light from the Federal Trade Commission last month, Amgen has completed the buyout and expects to provide updated fiscal year 2023 guidance during its third-quarter earnings call.

October 6, 2023
·
2 min read
·
Kate Goodwin
Drug Development

Amgen and US WorldMeds: A Tale of Data and Two FDA Adcomm Meetings

Though data became an issue in two separate meetings, the FDA’s Oncologic Drugs Advisory Committee made a potentially precedent-setting decision by voting in favor of US WorldMeds’ neuroblastoma treatment.

October 6, 2023
·
2 min read
·
Greg Slabodkin
Employer Resources

Webinar: Fostering Diversity & Inclusion in the Workplace

BioSpace was thrilled to host a virtual panel discussion to hear how workplaces can improve their D&I strategies and help organizations thrive. We heard insightful advice from panelists from Amgen, Intellia Therapeutics, Obsidian Therapeutics, Omega Therapeutics and Athira Pharma.

October 6, 2023
·
4 min read
·
Chantal Dresner
Employer Resources

Webinar: Recruiting Strategies for 2022: Winning Biopharma’s Struggle for Talent

In BioSpace’s latest webinar, we covered topics including proactive recruitment strategies, remote hiring, compensation negotiating and employee retention.

October 6, 2023
·
2 min read
·
Chantal Dresner
Opinion: Ozempic’s Pros, Cons and Correct Use Cases

Maximizing the true potential of Ozempic—and similar drugs—requires a partnership between drug developers, healthcare providers and patients.

October 6, 2023
·
5 min read
·
George Kramb
Employer Resources

Webinar: The New Hybrid Workplace: Creating Fair Policies

In this webinar, we discuss how to create policies that are fair for both remote and local workers; vaccination policies; travel policies; communication strategies and managing employee relations in regards to these changes.

October 6, 2023
·
3 min read
·
Chantal Dresner
Drug Development

Merck’s Keytruda Poised for Bladder Cancer Expansion with New Phase III Data

Keytruda’s winning streak in bladder continues with positive data from the Phase III AMBASSADOR study, showing significantly better disease-free survival in muscle-invasive urothelial carcinoma.

October 6, 2023
·
2 min read
·
Tristan Manalac